Head movement should create a transient pressure imbalance across the membranous inner ear. We used basic concepts offluid dynamics todevelop a theoretical model of the inner ear. According to this model, two contiguous fluidic systems-the perilymphatic system and the endolymphatic system-are in hydrostatic equilibrium across a compliant membrane. Our model demonstrates that changes in resistance or compliance in one system results in a transient distortion of the membranous inner earuntilequilibrium between thetwo systems isrestored. Theconcept of hydrodynamic pressure changes in theinnerear has received little attention, butit mayrepresent a newapproach tounderstanding theinner earandtreating inner eardiseases.
Introduction
While some cases of vertigo are easily diagnosed and treated, others present a challenge. New approaches to understanding the inner ear should be explored to help us better manage the challenging cases. We have developed a theoretical hydrodynamic model of the inner ear that may be useful in this regard.
Two proposed causes of vertigo are canalithiasis and cupulolithiasis, which are often cited to explain benign paroxysmal positional vertigo (BPPV) in particular. Rajguru et al developed a three-canal mathematical model of canalithiasis to explain why the Epley canalith repositioning maneuver is so effective in treating patients with BPPV.I However, the fact that not all patients respond to the Epley maneuver-suggests that a different etiology is involved, and this led to the theory of cupulolithiasis, which holds that dislodged otoconia irritate the cupula.
Our hydrodynamic model isbased on the relationship between the two fluidic systems in the inner ear: the perilymphatic system and the endolymphatic system. These two systems are separated by a compliant membrane (the membranous labyrinth), and in a steady state, they are in hydrodynamic equilibrium across this membrane. When movement occurs, however, the fluid dynamics of the systems is perturbed and a transient pressure imbalance develops. The time required for equilibrium to be regained depends on two variables: resistance to fluid flow and compliance of the system. With our theoretical model, we analyze the relationships among these variables, and weexpressthese relationships in mathematical formulas. Our model can be applied to the study of challenging cases of vertigo, BPPV, and Meniere disease.
The hydrodynamic model
Applying basic concepts offluid dynamics, we developed mathematical formulas that describe the relationships among various properties and actions of the perilymphaticand endolymphatic systems.Takinginto consideration three variables-volume (V), time to equilibrium (t),andpressure(P)-wecanmathematicallydefineflow (F), resistance (R), and compliance (C) thus:
Ifwe combine these expressions,the resulting formulas are as follows:
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Maintenance ofoverall system equilibrium across the membranous labyrinth requires that the RC products of both the perilymphatic (p) and endolymphatic (e) systems be equal-that is: RpC p = R.Ce" A change in any of these four factors (R , C , R , and C ), such as an Resistance is introduced into one of the tubes. When the structure is inverted, thepressure at A increases morerapidly than thepressure atA', and thepressure at B decreases morerapidly than the pressure at B'. As a result, a briefpressure differential occurs across the topand bottommembranes and theyaredistorted. Over time, the two systems eventually regain equilibrium (t = RC).
which can affect resistance or compliance, and changes in viscosity, which will affect resistance. These changes can result in a transient distortion of the membranous inner ear. The hydrodynamic model may help explain how symptoms of Meniere disease can be caused by obstructing lesions of the endolymphatic sac and how these symptoms are relieved by the Meniett device, an alternating pressure generator. Our model may also explain why some patients are more susceptible to Wright's Reprints 877 -652 -5295 sales@wrightsreprints.com BPPV and more resistant to treatment with canalith repositioning maneuvers.
In conclusion, the hydrodynamic model of the inner ear demonstrates how variations in the RC product of the two fluidic systems may contribute to inner ear dysfunction. Variations in resistance and compliance can result in a transient pressure imbalance, which might help explain the pathophysiology of conditions such as vertigo, BPPV, and Meniere disease. Future directions include constructing a physical model that can be modified by manipulating the resistance in the endolymphatic or perilymphatic system or by adding canaliths to the system.
